Virtual Library
Start Your Search
Ziyi Xu
Author of
-
+
P83 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Targeted Therapy (ID 260)
- Event: WCLC 2020
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P83.04 - Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent as Subsequent Therapy for Advanced NSCLC (ID 2909)
00:00 - 00:00 | Presenting Author(s): Ziyi Xu
- Abstract
Introduction
Previous studies have demonstrated that programmed cell death-1 (PD-1) inhibitors are effective in advanced or metastatic non-small-cell lung cancer (NSCLC) treatment. However, whether the combination of PD-1 inhibitors and anti-angiogenic targeting agents benefited advanced NSCLC patients remains unknown. In this study, we retrospectively reviewed the efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and anti-angiogenic targeting agent as subsequent therapy for NSCLC patients.
Methods
A total of twenty-nine evaluable patients with advanced or metastatic NSCLC who progressed after at least two cycles of platinum-based chemotherapy or targeted therapy and subsequently received the combination therapy of PD-1 inhibitor and anti-angiogenesis were included. Safety profile and efficacy were investigated.
Results
At the time of a median follow-up period of 9.8 months, 23 patients experienced progression of disease and 12 patients died because of disease. The median progression-free survival (mPFS) was 5.7 months (95%CI 3.018-8.402). The objective response rate (ORR) and the disease control rate (DCR) were 10.3% and 79.3% respectively (0 complete remission, 3 partial response and 20 stable disease). Patients with programmed cell death ligand-1 (PD-L1) expression on at least 1% of tumor cells (n=5) has relatively longer mPFS to compared to those with PD-L1-negative tumors (n=13), though no significant difference was observed (11.6 months versus 5.0 months, P=0.967). Two patients suspended therapy due to grade 3 immune-related pneumonia and pancreatitis respectively. One patient discontinued therapy because of grade 2 liver toxicity. Only two patient reported mild hemoptysis, and one patient reported grade 1 hypertension after administration of anti-angiogenetic agents.
Conclusion
Combination of PD-1 inhibitors and anti-angiogenic targeting agents is beneficial for patients with advanced or metastatic NSCLC as subsequent treatment, especially for patients with PD-L1 protein expression positive, and is well tolerated.
